Merck & Co., Inc - Company Snapshot & SWOT Analysis
Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The Company’s operations are principally managed on a products basis and include four operating segments, which are the Pharmaceutical, Animal Health, Healthcare Services and Alliances segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.
Merck reported revenue of USD 42.294 billion for the FY 2018 which saw an increase of 5.41% compared to FY 2017. This revenue is expected to increase by 5.68% and reach USD 44.700 billion by FY 2019.
Merck & Co., Inc. registered highest revenue from oncology (Keytruda, Emend, Temodar, Alliance revenue – Lynparza and Alliance revenue - Lenvima) at USD 8.243 billion which accounted for 21.87% of its total pharmaceuticals sales in FY 2018.
Looking into 2019, Merck said it sees non-GAAP earnings of between $4.57 and $4.72 per share on worldwide sales of between $43.2 billion and $44.7 billion.
Spanning over 29 pages and 13 exhibits, “Merck & Co., Inc - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Merck & Co., Inc - Company Snapshot & SWOT Analysis Report
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.
Merck reported revenue of USD 42.294 billion for the FY 2018 which saw an increase of 5.41% compared to FY 2017. This revenue is expected to increase by 5.68% and reach USD 44.700 billion by FY 2019.
Merck & Co., Inc. registered highest revenue from oncology (Keytruda, Emend, Temodar, Alliance revenue – Lynparza and Alliance revenue - Lenvima) at USD 8.243 billion which accounted for 21.87% of its total pharmaceuticals sales in FY 2018.
Looking into 2019, Merck said it sees non-GAAP earnings of between $4.57 and $4.72 per share on worldwide sales of between $43.2 billion and $44.7 billion.
Spanning over 29 pages and 13 exhibits, “Merck & Co., Inc - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Merck & Co., Inc - Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Merck & Co., Inc. including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Merck & Co., Inc.- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Merck & Co., Inc.
3.1.1 Company Profile
3.1.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Merck & Co., Inc.: Financial Performance
3.1.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.1.4 Merck & Co., Inc.: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Merck & Co., Inc.
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Company Information
Scope of the Merck & Co., Inc.- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Merck & Co., Inc.
3.1.1 Company Profile
3.1.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Merck & Co., Inc.: Financial Performance
3.1.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.1.4 Merck & Co., Inc.: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Merck & Co., Inc.
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Merck & Co.
Exhibit 3.2 Contact Information of Merck & Co.
Exhibit 3.3 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
Exhibit 3.6 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 3.7 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 3.8 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 3.9 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 3.10 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 3.11 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
Exhibit 3.12 SWOT Analysis of Merck & Co., Inc.
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Merck & Co.
Exhibit 3.2 Contact Information of Merck & Co.
Exhibit 3.3 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
Exhibit 3.6 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 3.7 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 3.8 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 3.9 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 3.10 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 3.11 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
Exhibit 3.12 SWOT Analysis of Merck & Co., Inc.
